GB2236249A - Acyclovir for treatment or prophylaxis of common cold - Google Patents

Acyclovir for treatment or prophylaxis of common cold Download PDF

Info

Publication number
GB2236249A
GB2236249A GB8915717A GB8915717A GB2236249A GB 2236249 A GB2236249 A GB 2236249A GB 8915717 A GB8915717 A GB 8915717A GB 8915717 A GB8915717 A GB 8915717A GB 2236249 A GB2236249 A GB 2236249A
Authority
GB
United Kingdom
Prior art keywords
acyclovir
treatment
common cold
medicament
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB8915717A
Other versions
GB8915717D0 (en
Inventor
Warren Alfred Nicholls
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB8915717A priority Critical patent/GB2236249A/en
Publication of GB8915717D0 publication Critical patent/GB8915717D0/en
Publication of GB2236249A publication Critical patent/GB2236249A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Acyclovir (2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]-6H-purin-6-one) is used for the manufacture of a medicament for the treatment or prophylaxis of the common cold. It can be administered in tablet or suspension form as part of a composition comprising pharmaceutically acceptable carriers and/or flavourings and/or other compatible pharmaceutical products. Suitable unit dosages of Acyclovir are in the range 200-800 mg, preferably 200 mg.

Description

DESCRIPTION PHARMACEUTICAL PRODUCTS The present invention relates to pharmaceutical products, and in particular to a product found to be effective in curing, preventing or at least alleviating or reducing the effects of the common cold.
The product Acyclovir (sold for example under the Trade Mark ZOVIRAX) is known in ointment form for use in the eye as a treatment for herpes simplex, keratisis and in tablet and suspension form for treatment and suppression of long term genital herpes, for treatment of herpes simplex infections of skin and human membranes, for treatment of acute herpes zoster infections and prophylaxis in immunocompromised patients.
It has now rather surprisingly been found that Acyclovir is effective in curing, preventing or at least alleviating or reducing the effects of the common cold.
According to the present invention therefore, there is provided Acyclovir for use in combatting the common cold and its effects.
The Acyclovir may be administered wnen the patient has already caught the cold to cure or at least alleviate or reduce the cold and/or its symptoms or it may be administered as a preventative medicament.
Acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one.
The Acyclovir may be administered in any convenient form, e.g. tablet or suspension and the invention also includes therefore a composition comprising Acyclovir together with one or. more pharmaceutically acceptable carriers and/or flavourings. In addition, one or more compatible pharmaceutical products may be included in the composition. The amount of active ingredient (Acyclovir) in the composition may vary, but is preferably in the range 200-800 mg per unit dosage.
The most preferred forms are tablets including 200 mg of Acyclovir per tablet and suspensions containing 20Q mg Acyclovir per 5 mils.
The dosage recommended can also vary widely, but preferably in the range of 1000-4000 mg of Acyclovir per day administered usually in a number of doses, e.g. five tablets taken every four hours (maximum five in any twentyfour-hour period) for five days.
Acyclovir has no known harmful side effects.

Claims (7)

1. Use of Acyclovir for the manufacture of a medicament for the treatment of the common cold.
2. Use of Acyclovir for the manufacture of a medicament for the prophylaxis of the common cold.
3. Use of Acyclovir according to claim 1 or claim 2, wherein the medicament is in unit dosage form.
4. Use of Acyclovir according to claim 3, wherein the medicament contains 200-800 mg of Acyclovir per unit dosage.
5. Use of Acyclovir according to claim 3, wherein the medicament contains 200mg of Acyclovir and is in the form of a tablet or of a 5ml suspension.
6. Use of Acyclovir according to any preceding claim, wherein the medicament comprises one or more pharmaceutically acceptable carriers and/or flavourings and/or other compatible pharmaceutical products.
7. Use of Acyclovir according to any preceding claim, substantially as described herein.
GB8915717A 1989-07-08 1989-07-08 Acyclovir for treatment or prophylaxis of common cold Withdrawn GB2236249A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB8915717A GB2236249A (en) 1989-07-08 1989-07-08 Acyclovir for treatment or prophylaxis of common cold

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8915717A GB2236249A (en) 1989-07-08 1989-07-08 Acyclovir for treatment or prophylaxis of common cold

Publications (2)

Publication Number Publication Date
GB8915717D0 GB8915717D0 (en) 1989-08-31
GB2236249A true GB2236249A (en) 1991-04-03

Family

ID=10659778

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8915717A Withdrawn GB2236249A (en) 1989-07-08 1989-07-08 Acyclovir for treatment or prophylaxis of common cold

Country Status (1)

Country Link
GB (1) GB2236249A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURR. THER.(AUSTRALIA),VOL.25,NO.2,1984,PAGES 13-20. *

Also Published As

Publication number Publication date
GB8915717D0 (en) 1989-08-31

Similar Documents

Publication Publication Date Title
IE892061L (en) Therapeutic nucleosides
CA2130755A1 (en) Intermediates useful in the preparation of purine nucleoside analogues
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
MY103760A (en) Therapeutic nucleosides
BR9306841A (en) Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment
EP0294114A3 (en) Antiviral compounds
CY2512B1 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
MX173567B (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
AU6005586A (en) Antiviral compounds
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
EP0351215A3 (en) Ester of 9-(2-hydroxyethoxymethyl) guanine
JP2008088189A (en) Use of aminopurine antiviral agent for treatment and prophylaxis of latent herpesvirus infection
IE892654L (en) Therapeutic nucleosides
US5886047A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
GB2236249A (en) Acyclovir for treatment or prophylaxis of common cold
DK175078B1 (en) Use of 15-deoxypergualin for the manufacture of a medicament for the therapeutic treatment of central nervous system degenerative diseases
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
JP4166955B2 (en) View propion for treating viral diseases
CA2255856A1 (en) Therapeutic uses for an aminosterol compound
EP0346108A3 (en) Anti-infective nucleosides
Miller Use of levamisole in recurrent aphthous stomatitis
US4751236A (en) Method for treating genital herpes
Kangasniemi Placebo, 1‐Isopropylnoradrenochrome‐5‐Monosemicarbazono and Pizotifen in Migraine Prophylaxis

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)